• Hemab Therapeutics flagged new first-in-human results for HMB-002 in Von Willebrand disease, scheduled for presentation at the ISTH 2026 Congress in July.
• The early readout supports the drug’s intended effect, lifting key clotting proteins with subcutaneous dosing, with no clot-related safety signal reported.
• A multiple-dose assessment is underway, positioning the program toward a potential prophylactic use case in Von Willebrand disease.
• Hemab also introduced HMB-003, a long-acting plasmin inhibitor, with first-in-human studies planned for 2H 2026 and heavy menstrual bleeding studies targeted for 2027.
• Separately, long-term Phase 2 extension data for sutacimig in Glanzmann thrombasthenia will be presented at ISTH, ahead of a Phase 3 start planned for 2H 2026.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Hemab Therapeutics Holdings Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202606260900PRIMZONEFULLFEED9752913) on June 26, 2026, and is solely responsible for the information contained therein.